1-6 of 6
Karima Imadalou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Mark J. Levis, Pau Montesinos, Hee-Je Kim, Radovan Vrhovac, Elzbieta Patkowska, Pavel Zak, Po-Nan Wang, Jorge E. Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Alexander E. Perl, Mitsuhiro Yazawa, Jaime E. Connolly Rohrbach, Venkat Thodima, Ken C. N. Chang, Li Liu, Karima Imadalou, Akash Nahar, Kristy Burns, Harry P. Erba
Journal: Blood
Blood (2024) 144 (Supplement 1): 848.
https://doi.org/10.1182/blood-2024-203303
Published: 2024
Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Pau Montesinos, June-Won Cheong, Naval Daver, Amir T. Fathi, Mark J. Levis, Selina Luger, Toshihiro Miyamoto, Esther Natalie Oliva, Alexander E. Perl, Christian Récher, Richard F. Schlenk, Jianxiang Wang, Amer M. Zeidan, Li Liu, Yvonne Duong, Karima Imadalou, Karenza Alexis, Akash Nahar, Kristy Burns, Harry P. Erba
Journal: Blood
Blood (2024) 144 (Supplement 1): 1504.3.
https://doi.org/10.1182/blood-2024-205101
Published: 2024
Journal Articles

Quantum-First: Effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication-Positive ( FLT3 -ITD+) Acute Myeloid Leukemia (AML) Who Received Continuation (CONT) Therapy (tx)

Mark J. Levis, Harry Erba, Pau Montesinos, Elzbieta Patkowska, Jorge E. Cortes, Herve Dombret, Alexander E. Perl, Sergio Amadori, Jianxiang Wang, Richard F. Schlenk, Li Liu, Yasser M. Mostafa Kamel, Karima Imadalou, Abderrahmane Laadem, Mikkael A. Sekeres, Kristy Burns
Journal: Blood
Blood (2024) 144 (Supplement 1): 2890.
https://doi.org/10.1182/blood-2024-207305
Published: 2024
Journal Articles

Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD) Positive Acute Myeloid Leukemia (AML)

Harry P. Erba, Herve Dombret, Alexander Perl, Tsvetomir Mitov, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Youngsook Choi, Mark J. Levis, Richard F Schlenk
Journal: Blood
Blood (2023) 142 (Supplement 1): 972.
https://doi.org/10.1182/blood-2023-186206
Published: 2023
Journal Articles

Kinetics of Complete Remission (CR) and CR Duration and Its Impact on Overall Survival (OS) and Event-Free Survival (EFS) in Quantum-First

Pau Montesinos, Alexander Perl, Mikkael A. Sekeres, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Richard F Schlenk, Harry P. Erba, Hervé Dombret
Journal: Blood
Blood (2023) 142 (Supplement 1): 4254.
https://doi.org/10.1182/blood-2023-187286
Published: 2023
Journal Articles

Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3 -ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) FLT3 -ITD+ AML Patients (pts)

Alexander Perl, Harry P. Erba, Pau Montesinos, Radovan Vrhovac, Elzbieta Patkowska, Heeje Kim, Pavel Zak, Po-Nan Wang, Jaime E Rohrbach, Ken C N Chang, Li Liu, Yasser Mostafa Kamel, Karima Imadalou, Arnaud Lesegretain, Jorge Cortes, Mikkael A. Sekeres, Hervé Dombret, Sergio Amadori, Jianxiang Wang, Richard F Schlenk, Mark J. Levis
Journal: Blood
Blood (2023) 142 (Supplement 1): 832.
https://doi.org/10.1182/blood-2023-186785
Published: 2023